Frontiers in Clinical Drug Research – Anti-Cancer Agents
Bentham Science has recently launched the new volume of the book, Frontiers in Clinical Drug…
prostate cancer
City of Hope opens Phase 2 trial to test if mushroom tablets could slow prostate cancer
Scientists investigate if City of Hope’s natural supplement derived from white button mushroom could lower prostate-specific antigen levels, an indicator of prostate cancer
Male bladder cancer vulnerability could lead to a new treatment approach
UC Davis Comprehensive Cancer Center researchers found that targeting androgen receptors – a type of protein specific to men – may destroy cancer cells. Focusing on this male protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer in men.
12 open arms in NCI-MATCH treatment trial await patients with advanced or rare cancers
A new study arm opens, expanding patients’ potential to qualify for the trial when they may not have other options; the available treatments target tumor defects with drugs that show efficacy evidence; testing labs continue to identify trial candidates
First clinical trials set for MRI cancer detection
Case Western Reserve University-developed imaging agent for MRI prostate cancer detection gets FDA approval for safety trials, set to begin in May in Columbus
New Urine-based Test Holds Promise for Detecting Aggressive Prostate Cancer
A new, urine-based test for aggressive prostate cancer being developed at the University of Michigan uses next-generation sequencing to assess 15 biomarkers to find cancer that can be missed by biopsies or imaging tests.
Novel drug regenerates erectile nerves damaged by prostate surgery
April 19, 2021–(BRONX, NY) –Researchers at Albert Einstein College of Medicine have developed a topical…
Bone microenvironment fosters breast cancer metastatic behavior
Two studies led by Baylor College of Medicine shed new light on the unanswered question…
Study: New Approach May Boost Prostate Cancer Immunotherapies
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Study: New approach may boost prostate cancer immunotherapies
Strategy focuses on reprogramming tissues surrounding the tumor to help the body’s immune system attack the cancer
Researchers Awarded Funding to Lead National Discussion on Active Surveillance for Men with Low-Risk Prostate Cancer
Researchers at the University of Maryland School of Medicine (UMSOM) have been awarded $100,000 in funding through the Eugene Washington PCORI Engagement Awards, an initiative of the Patient-Centered Outcomes Research Institute (PCORI). The funds will support a national discussion and conference aimed at identifying evidence gaps to guide future research on the use of active surveillance to monitor low-risk prostate cancers. This serves as an alternative to immediate treatment with surgery, radiation or hormone therapy which all have potential debilitating side effects.
John D. Carpten elected fellow of AACR Academy
American Association for Cancer Research honors distinguished USC Norris Comprehensive Cancer Center scientist
CTC mutations may predict outcomes in some castrate-resistant prostate cancer patients
Bottom Line: Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes…
NCCN 2021 Virtual Annual Conference addresses cancer care in a year of crisis and innovation
Live virtual conference drew global oncology professionals to share best practices and highlight advances and issues in cancer care
Oncotarget: Phase 1 study of Z-Endoxifen in patients with solid tumors
The Oncotarget article provides evidence that antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy.
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than…
Drug used during pregnancy may increase cancer risk in mother’s adult children
Exposure in the womb to a drug used to prevent miscarriage appears to raise the offspring’s cancer risk decades later, especially for colorectal and prostate cancers, researchers have found. They will present the results of their new study Tuesday at ENDO 2021, the Endocrine Society’s annual meeting.
Increasing diversity in clinical trials the focus of new stand up to cancer team
The Health Equity Breakthrough Team includes clinical cancer specialists and experts in the social science components of community health
Drug used during pregnancy may increase cancer risk in mother’s adult children
Hydroxyprogesterone caproate may contribute to increasing rates of early-onset cancer, researchers say
Prostate cancer uses metabolic switch to thrive after hormone therapy
Finding points toward a new approach that directly targets the cancer’s fuel source
Study could help develop biosensors for non-invasive diagnosis of diseases
Brazilian researchers tested the capacity of different materials to produce sensors for the detection of PCA3, a gene that is overexpressed in prostate cancer. The technique can also be used to diagnose infectious diseases, including COVID-19.
Oncotarget: Hispanic Chronic myelomonocytic leukemia patients
This Oncotarget study had significantly lower mutation rates in ASXL1 and SETBP1, and a higher rate of muTET2/wtASXL1
Oncotarget: Ibuprofen disrupts protein complex in colorectal cells
The Oncotarget data shed new light on the biochemical mechanisms behind ibuprofen’s action on alternative spliced RAC1B and may support its use in personalized approaches to CRC therapy or chemoprevention regimens.
Oncotarget: Predictors of immunotherapy benefit in Merkel cell carcinoma
Dr. Glenn J. Hanna from CCR/NCI in Bethesda, MD as well as The Dana-Farber Cancer Institute in Boston Massachusetts said, “Merkel cell carcinoma (MCC) is a relatively rare cancer, with roughly 400 cases per 100,000 persons each year in the United States”
Having a single personal doctor may sometimes lead to unnecessary tests
Patient care by a single primary care physician is associated with many health benefits, including…
White button mushrooms could slow progression of prostate cancer
The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
White button mushrooms could slow progression of prostate cancer
Mouse study suggests mushrooms may suppress androgen receptor activity
LSU Veterinary School receives $11M COBRE grant for a pre-clinical cancer research center
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11…
Oncotarget: Quantitative proteome profiling stratifies fibroepithelial lesions of the breast
The present Oncotarget work shed light on a brief mechanistic framework of PTs aggressive nature and present potential biomarkers to differentiate overlapping FELs that would be of practical utility in augmenting existing diagnosis and disease management
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
Cancer mutations insight could boost detection and personalize treatments
The understanding of many common cancers could be revolutionized by the discovery that in some cases the disease is partly triggered by large numbers of inherited genetic mutations — previously thought to have little impact on cancer risk
Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC
Doctors should address reduced sense of taste and smell in cancer patients, Tulane study says
The study is a joint project of the Tulane Department of Psychology and the Tulane Cancer Center.
Oncotarget: A novel isoform of Homeodomain-interacting protein kinase-2
This @Oncotarget study indicates that HIPK2 isoform 3, the main HIPK2 isoform expressed in NSCLC, promotes YAP/TEAD transcriptional activity in NSCLC cells
Oncotarget: Folinic acid in colorectal cancer: Esquire or fellow knight?
Showing a clear clinical benefit for patients, irrespective of RAS mutational status, primitive tumor side and metastases surgery
Oncotarget: MicroRNA-4287 is controlling epithelial-to mesenchymal transition in prostate cancer
miR-4287 has potential diagnostic and therapeutic significance in preventing advanced, metastatic disease
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.
Henry Ford Cancer Institute aims to increase minority participation in clinical trials
$750,000 grant from Genentech will support collaboration with the Detroit Urban Research Center
Targeted screening for prostate cancer could prevent one in six deaths
Peer-reviewed | modelling | people
New AI approach enables research collaboration while protecting patient privacy
Dr. Corey Arnold and his graduate student, Karthik Sarma, explain how federated learning can enable more powerful AI models while enhancing the protection of patient data
Predicting success in therapy with individualized cancer models
In the EU alone, 78,800 men died of prostate cancer last year. While tumors discovered…
Oncotarget: Estrogen receptor α polymorphism is associated with dementia
“In conclusion, estrogen receptor α PvuII polymorphism is associated with dementia in a Brazilian cohort”
Oncotarget: High-fat ovariectomized mice susceptible to accelerated tumor growth
There is convincing evidence that excess body weight is associated with increased risk for late onset (> 50 years of age) colorectal cancer (CRC)
Oncotarget: Sensitivity testing on ovarian cancer cells isolated from malignant ascites
The aim of this @Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays
$1m grant funds research on potential new RX for prostate cancer
New Orleans, LA – The Biomedical Laboratory Research and Development Branch of the Veterans Administration…
NE Ohio initiative to increase prostate cancer screening in African Americans
Supported with three-year, $2.75M grant from Bristol Myers Squibb Foundation
Natural product isolated from sea sponge tested against cancer cells
Scientists from Far Eastern Federal University (FEFU) together with Russian and German colleagues, continue studying…
Oncotarget: Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma
The @Oncotarget authors aimed to assess the effect of cirrhosis on outcomes in iCCA patients
Oncotarget: Exploiting the metabolic dependencies of the broad amino acid transporter SLC6A14
“Suggesting that combined targeting of SLC6A14 and AMPK can be exploited as a therapeutic approach to starve tumor cells”
Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma
“Elevated PLT count seems to identify a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC”